CNTY 102
Alternative Names: CNTY-102Latest Information Update: 13 Apr 2024
At a glance
- Originator Century Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical B-cell lymphoma
Most Recent Events
- 09 Apr 2024 Interim pharmacodynamics data from a preclinical studies of B-cell lymphoma released by Century Therapeutics
- 10 May 2023 Preclinical trials in B-cell lymphoma in USA (Parenteral) (Century Therapeutics pipeline, May 2023)
- 24 Mar 2022 Century Therapeutics announces intention to submit IND application to regulatory bodies for B-cell lymphoma in 2024